At-Home Molecular Testing Market Revenue is Expected to Reach US$16.3 Billion by the end of 2030, By Persistence Market Research
17 janv. 2024 00h58 HE | Persistence Market Research
New York, Jan. 17, 2024 (GLOBE NEWSWIRE) -- At-Home Molecular Testing Market: A Booming Frontier in Healthcare At-Home Molecular Testing refers to the use of molecular diagnostic tests conducted in...
Featured Image for P23 Health
P23 Health E-Commerce Well-Being Company Just Launched in Partnership With P23 Labs, a Renowned Molecular Laboratory
03 nov. 2022 09h15 HE | P23 Health
SAVANNAH, Ga., Nov. 03, 2022 (GLOBE NEWSWIRE) -- P23 Health is a newly formed digital healthcare and wellness company under the P23 umbrella. P23 Health's strategic partner is acknowledged molecular...
MAKO Medical Invests in New Laboratory Automation
MAKO Medical Invests in New Laboratory Automation
18 juil. 2022 07h10 HE | MAKO Medical
RALEIGH, N.C., July 18, 2022 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and national leader in COVID-19 testing, is purchasing four additional high-tech liquid...
Straits Research Pvt Ltd
Genetic Testing Market is projected to reach USD 36.11 Billion by 2030, growing at a CAGR of 10%: Straits Research
16 juin 2022 15h40 HE | Straits Research
New York, United States, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic testing examines DNA to find gene mutations linked to a wide range of hereditary illnesses. There are multiple forms of genetic...
PRPO logo.png
Current Signed Customers Expected to Generate $1M Annualized Reported Revenues from Precipio’s HemeScreen POL Offering by Q4-2021
26 avr. 2021 11h00 HE | Precipio, Inc.
NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that currently, the contracted annualized revenues from signed customers...
PRPO logo.png
Precipio Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor
10 déc. 2020 10h15 HE | Precipio, Inc.
NEW HAVEN, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) has entered into an agreement with a major US-based oncology distributor to...
IDXG Logo.jpg
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
25 avr. 2019 06h55 HE | Interpace Diagnostics Group, Inc.
Pennsylvania and Connecticut Labs Both Receive Accreditation PARSIPPANY, NJ, April 25, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has...
IDXG Logo.jpg
Interpace Diagnostics Announces New York State Approval
23 avr. 2019 06h55 HE | Interpace Diagnostics Group, Inc.
State of New York Approves Commercialization of ThyraMIR® Now in Three Specimens PARSIPPANY, NJ, April 23, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today...
gmi 2018.png
In-vitro Diagnostic Services Market worth over $63 billion by 2024: Global Market Insights, Inc.
13 sept. 2018 06h00 HE | Global Market Insights, Inc
Sellbyville, Delaware, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Global In-vitro Diagnostic Services Market is poised to cross USD 63 billion by 2024; according to a new research report by Global Market...
IASLC-Logos-HZ-tag - Copy - Copy.jpg
IASLC邀请肺癌专业人士参与全球分子诊断调查
12 juil. 2018 16h11 HE | IASLC
丹佛, July 13, 2018 (GLOBE NEWSWIRE) -- 国际肺癌研究协会(IASLC)鼓励所有参与肺癌患者分子诊断的人员参加一项全球调查,本调查旨在评估最佳实务的实施情况及最终制定分子诊断的全球指南。欲参加IASLC肺癌分子诊断全球调查,请访问www.iaslc.org/survey。 IASLC的医学博士、哲学博士和首席执行官Fred R....